Oncology (all articles)
RCT: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer.
1 Jul, 2022 | 10:28h | UTCCommentary: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive
Commentary on Twitter
Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt
— Paolo Tarantino (@PTarantinoMD) June 28, 2022
Opinion | Renaming Gleason Score 6 prostate to noncancer: a flawed idea scientifically and for patient care.
30 Jun, 2022 | 10:44h | UTCOriginal Opinion Paper: Low-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors.
30 Jun, 2022 | 10:16h | UTC
ASCO Guideline Update: Biomarkers for systemic therapy in metastatic breast cancer.
29 Jun, 2022 | 11:40h | UTC
Commentary on Twitter
‼️ ? @ASCO guideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡️ https://t.co/qAzT9WNKTF #bcsm #biomarkers @AngieDemichele pic.twitter.com/3WtAt8TK5w
— Journal of Clinical Oncology (@JCO_ASCO) June 27, 2022
Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.
29 Jun, 2022 | 10:59h | UTC
RCT: Maintenance Taxanes vs. surveillance in women with advanced ovarian/tubal/peritoneal cancer.
29 Jun, 2022 | 10:57h | UTCPhase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Consensus Guideline: Diagnosis and treatment of Merkel cell carcinoma.
28 Jun, 2022 | 11:07h | UTC
Study: Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer.
28 Jun, 2022 | 10:32h | UTCBiochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 – Journal of Clinical Oncology (link to abstract – $ for full-text)
Phase 2 RCT: Durvalumab plus Olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma.
28 Jun, 2022 | 10:31h | UTCDurvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Results from Durva+/-Olaparib in 1L platinum ineligible mUC published in JCO. No benefit in ITT, but prolonged PFS in HRRm patients. Worthy of further investigation. Tough trial to do, made possible by great international team. @MSKCancerCenter @JCO_ASCO https://t.co/9hQNYoR5OE pic.twitter.com/bz1wTAXp7K
— Jonathan Rosenberg MD (@DrRosenbergMSK) June 24, 2022
Consensus Statement: First-line PARP inhibitor maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
27 Jun, 2022 | 11:34h | UTC
RCT: Efficacy of Ipilimumab vs. FOLFOX in combination with Nivolumab and Trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma.
27 Jun, 2022 | 11:11h | UTCEfficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma – JAMA Oncology (free for a limited period)
Cohort Study: Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer.
27 Jun, 2022 | 11:09h | UTCPrognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Is #HER2low a distinct BC subtype? Among >5000 pts from DFCI/Brigham, we found no relevant difference between HER2-low & HER2-0 BC. ER-exp determined disease behavior & was positively associated with HER2-low exp. Huge thanks to @stolaney1 & all coauthors!https://t.co/OfGT8LS2pH pic.twitter.com/uFxXGvOI8S
— Paolo Tarantino (@PTarantinoMD) June 23, 2022
Systematic Review: Locally recurrent rectal cancer according to a standardized MRI classification system.
27 Jun, 2022 | 11:07h | UTC
M-A: Relationship between serum lipid level and colorectal cancer.
27 Jun, 2022 | 11:01h | UTC
Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.
24 Jun, 2022 | 11:07h | UTC
Single-arm phase II study: EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
24 Jun, 2022 | 10:49h | UTCEZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma.
24 Jun, 2022 | 10:46h | UTCLongitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
News Release: Non-invasive liquid biopsy tracks cancer treatment success in real time – University of Wisconsin–Madison
Commentary: Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – The ASCO Post
Commentary on Twitter
? Longitudinal analysis of circulating tumor cells from metastatic #RenalCellCarcinoma provides insight into changes in both tumor burden & #MolecularProfile of tumor cells in response to treatment. #JCO #kcsm @joshlangmd https://t.co/fPU8PepHJR pic.twitter.com/cKPvXiPB0W
— Journal of Clinical Oncology (@JCO_ASCO) June 10, 2022
Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.
23 Jun, 2022 | 10:26h | UTC
International consensus statements on pre-invasive vulvar lesions.
23 Jun, 2022 | 10:21h | UTCNews Release: New Guidelines Address Treatment of Pre-Invasive Lesions of the Vulva – Wolters Kluwer Health: Lippincott
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
Phase II RCT: FLOT vs. FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma.
23 Jun, 2022 | 09:58h | UTCFLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group – Journal of Clinical Oncology (link to abstract – $ for full-text)
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.
23 Jun, 2022 | 09:57h | UTC
Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
23 Jun, 2022 | 09:54h | UTC
ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.
22 Jun, 2022 | 11:30h | UTC
Cohort Study: Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment.
22 Jun, 2022 | 10:51h | UTCCommentaries:
Polypharmacy can lead to harmful drug interactions, especially among cancer patients – News Medical
Analysis Underscores Risks of Polypharmacy in Elderly Patients With Cancer – AJMC
Commentary on Twitter
Our new article in @OncJournal : In a large cohort of older adults with advanced cancer, polypharmacy &PIM are very common. Nonprescription meds are frequently PIMs &involved in potential harmful drug interactions @WilmotCancer @rochgerionc @myCARGhttps://t.co/bA7W4kyybm pic.twitter.com/zFI3EgS320
— Mostafa R Mohamed (@m_refaat84) April 2, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license